Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$2.58
-0.02 (-0.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-59.7M · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.6B
P/E
2.0x
↓EV/EBITDA
1.6x
↓ROE
109.9%
↑Gross Margin
56.9%
↑Debt/Equity
0.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+203.7%
FCF CAGR
—
FCF margin
-12.1%
FCF / Net income
-0.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $492.9M · net income $1.11B · FCF $-59.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $492.9M | $492.9M | $255.9M | $76.6M | $17.6M |
| Net Income | $1.11B | $1.11B | $-250.1M | $-211.2M | $-203.5M |
| EBITDA | $1.15B | $1.15B | $-207.0M | $-167.1M | $-168.1M |
| EPS | 1.10 | 1.10 | -0.25 | -0.22 | -0.21 |
| Gross Margin | 56.9% | 56.9% | 48.7% | 48.8% | 43.7% |
| Operating Margin | -27.6% | -27.6% | -137.8% | -377.4% | -1367.5% |
| Net Margin | 224.4% | 224.4% | -97.8% | -275.7% | -1156.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.30 | 0.30 | -2.22 | 1.66 | 0.35 |
| Current Ratio | 6.17 | 6.17 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-59.7M | $-59.7M | $-421.8M | $879.5M | $-257.6M |
| Returns | |||||
| ROE | 109.9% | 109.9% | 184.7% | -208.8% | -72.8% |
| Valuation | |||||
| P/E | 2.03 | 2.03 | — | — | — |
| EV/EBITDA | 1.57 | 1.57 | — | — | — |
| P/B | 2.58 | 2.58 | — | 22.80 | 14.38 |
| Growth & Yield | |||||
| Revenue Growth | 92.6% | 92.6% | 234.0% | 335.3% | — |
| EPS Growth | 540.0% | 540.0% | -13.6% | -4.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-40.7%
EPS terminal req.
$0.23
Spread vs growth
580.7%
5Y implied EPS CAGR
-24.1%
EPS terminal req.
$0.28
Spread vs growth
564.1%
10Y implied EPS CAGR
-8.6%
EPS terminal req.
$0.45
Spread vs growth
548.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+12.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.25 → 1.10
Residual
+12.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.